Department of Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.
Department of Molecular Haematology, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Hemoglobin. 2021 Jul;45(4):265-268. doi: 10.1080/03630269.2021.1981370. Epub 2021 Oct 6.
We present case histories of three patients who had β-thalassemia (β-thal) trait with 'unusual severity' managed as β-thal intermedia (β-TI) where the basis of disease severity could not be explained with routine hematological and genetic investigations. The clinical diagnosis of 'thalassemia intermedia' was justifiable as they had a β-thal mutation and disease severity that did not fit in with either β-thal trait or with β-thal major (β-TM). As mutations of α, β, and γ genes could not explain the unusual severity of the disease, further analysis with next-generation sequencing (NGS) for red cell diseases was carried out, which led to the diagnosis of coexisting membranopathies. This case series highlights the inherent difficulty in the diagnosis of β-TI with certainty in some patients where the genetic basis is not clear-cut.
我们呈现了三例β-地中海贫血(β-thal)特征伴有“异常严重”的病例,这些患者被诊断为β-中间型地中海贫血(β-TI),而常规血液学和遗传学检查无法解释其疾病严重程度的原因。由于他们有β-地中海贫血突变和疾病严重程度既不符合β-地中海贫血特征,也不符合β-重型地中海贫血(β-TM),因此临床诊断为“中间型地中海贫血”是合理的。由于α、β 和γ基因突变不能解释疾病的异常严重程度,因此对红细胞疾病进行了下一代测序(NGS)的进一步分析,从而诊断出同时存在的膜病变。本病例系列强调了在某些患者中,β-TI 的明确诊断存在固有困难,因为其遗传基础不明确。